Literature DB >> 11113205

Efficiency alleles of the Pctr1 modifier locus for plasmacytoma susceptibility.

S L Zhang1, W DuBois, E S Ramsay, V Bliskovski, H C Morse, L Taddesse-Heath, W C Vass, R A DePinho, B A Mock.   

Abstract

The susceptibility of BALB/c mice to pristane-induced plasmacytomas is a complex genetic trait involving multiple loci, while DBA/2 and C57BL/6 strains are genetically resistant to the plasmacytomagenic effects of pristane. In this model system for human B-cell neoplasia, one of the BALB/c susceptibility and modifier loci, Pctr1, was mapped to a 5.7-centimorgan (cM) chromosomal region that included Cdkn2a, which encodes p16(INK4a) and p19(ARF), and the coding sequences for the BALB/c p16(INK4a) and p19(ARF) alleles were found to be polymorphic with respect to their resistant Pctr1 counterparts in DBA/2 and C57BL/6 mice (45). In the present study, alleles of Pctr1, Cdkn2a, and D4Mit15 from a resistant strain (BALB/cDAG) carrying DBA/2 chromatin were introgressively backcrossed to the susceptible BALB/c strain. The resultant C.DAG-Pctr1 Cdkn2a D4Mit15 congenic was more resistant to plasmacytomagenesis than BALB/c, thus narrowing Pctr1 to a 1.5-cM interval. Concomitantly, resistant C57BL/6 mice, from which both gene products of the Cdkn2a gene have been eliminated, developed pristane-induced plasma cell tumors over a shorter latency period than the traditionally susceptible BALB/cAn strain. Biological assays of the p16(INK4a) and p19(ARF) alleles from BALB/c and DBA/2 indicated that the BALB/c p16(INK4a) allele was less active than its DBA/2 counterpart in inducing growth arrest of mouse plasmacytoma cell lines and preventing ras-induced transformation of NIH 3T3 cells, while the two p19(ARF) alleles displayed similar potencies in both assays. We propose that the BALB/c susceptibility/modifier locus, Pctr1, is an "efficiency" allele of the p16(INK4a) gene.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11113205      PMCID: PMC88804          DOI: 10.1128/MCB.21.1.310-318.2001

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  46 in total

1.  Clonal diversification of primary BALB/c plasmacytomas harboring T(12;15) chromosomal translocations.

Authors:  A L Kovalchuk; E B Mushinski; S Janz
Journal:  Leukemia       Date:  2000-05       Impact factor: 11.528

2.  Analysis of the hereditary pancreatitis-associated cationic trypsinogen gene mutations in exons 2 and 3 by enzymatic mutation detection from a single 2.2-kb polymerase chain reaction product.

Authors:  M E Ford; D C Whitcomb
Journal:  Mol Diagn       Date:  1999-09

3.  Analysis of cell-cycle profiles in transfected cells using a membrane-targeted GFP.

Authors:  W Jiang; T Hunter
Journal:  Biotechniques       Date:  1998-03       Impact factor: 1.993

4.  Germline CDKN2A mutation implicated in predisposition to multiple myeloma.

Authors:  D Dilworth; L Liu; A K Stewart; J R Berenson; N Lassam; D Hogg
Journal:  Blood       Date:  2000-03-01       Impact factor: 22.113

5.  Site-directed mutagenesis by overlap extension using the polymerase chain reaction.

Authors:  S N Ho; H D Hunt; R M Horton; J K Pullen; L R Pease
Journal:  Gene       Date:  1989-04-15       Impact factor: 3.688

6.  The genetics of susceptibility to RIM-induced plasmacytomagenesis.

Authors:  B Mock; J Wax; R Clynes; K B Marcu; M Potter
Journal:  Curr Top Microbiol Immunol       Date:  1988       Impact factor: 4.291

7.  A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage.

Authors:  H Tanaka; H Arakawa; T Yamaguchi; K Shiraishi; S Fukuda; K Matsui; Y Takei; Y Nakamura
Journal:  Nature       Date:  2000-03-02       Impact factor: 49.962

8.  Analysis of point mutation in exon 2 of CYP2E1 gene in renal cell/urothelial cancer patients in comparison with control population.

Authors:  K Farker; M H Lehmann; R Kästner; J Weber; V Janitzky; J Schubert; A Hoffmann
Journal:  Int J Clin Pharmacol Ther       Date:  2000-01       Impact factor: 1.366

9.  The bovine papillomavirus E5 oncogene can cooperate with ras: identification of p21 amino acids critical for transformation by c-rasH but not v-rasH.

Authors:  B M Willumsen; W C Vass; T J Velu; A G Papageorge; J T Schiller; D R Lowy
Journal:  Mol Cell Biol       Date:  1991-12       Impact factor: 4.272

10.  Rapid induction of IgM-secreting murine plasmacytomas by pristane and an immunoglobulin heavy-chain promoter/enhancer-driven c-myc/v-Ha-ras retrovirus.

Authors:  R Clynes; J Wax; L W Stanton; S Smith-Gill; M Potter; K B Marcu
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

View more
  23 in total

1.  Pitx2a expression alters actin-myosin cytoskeleton and migration of HeLa cells through Rho GTPase signaling.

Authors:  Qize Wei; Robert S Adelstein
Journal:  Mol Biol Cell       Date:  2002-02       Impact factor: 4.138

2.  IL-6 transgenic mouse model for extraosseous plasmacytoma.

Authors:  Alexander L Kovalchuk; Joong Su Kim; Sung Sup Park; Allen E Coleman; Jerrold M Ward; Herbert C Morse; Tadamitsu Kishimoto; Michael Potter; Siegfried Janz
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

3.  Obligate roles for p16(Ink4a) and p19(Arf)-p53 in the suppression of murine pancreatic neoplasia.

Authors:  Nabeel Bardeesy; Jeffrey Morgan; Manisha Sinha; Sabina Signoretti; Shefali Srivastava; Massimo Loda; Glenn Merlino; Ronald A DePinho
Journal:  Mol Cell Biol       Date:  2002-01       Impact factor: 4.272

Review 4.  Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma.

Authors:  Timothy R Rosean; Van S Tompkins; Guido Tricot; Carol J Holman; Alicia K Olivier; Fenghuang Zhan; Siegfried Janz
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

5.  Activated gp130 signaling selectively targets B cell differentiation to induce mature lymphoma and plasmacytoma.

Authors:  Anna K Scherger; Mona Al-Maarri; H. Carlo Maurer; Markus Schick; Sabine Maurer; Rupert Öllinger; Irene Gonzalez-Menendez; Manuela Martella; Markus Thaler; Konstanze Pechloff; Katja Steiger; Sandrine Sander; Jürgen Ruland; Roland Rad; Leticia Quintanilla-Martinez; Frank T Wunderlich; Stefan Rose-John; Ulrich Keller
Journal:  JCI Insight       Date:  2019-08-08

6.  The transcription factor MZF1 differentially regulates murine Mtor promoter variants linked to tumor susceptibility.

Authors:  Shuling Zhang; Wei Shi; Edward S Ramsay; Valery Bliskovsky; Adrian Max Eiden; Daniel Connors; Matthew Steinsaltz; Wendy DuBois; Beverly A Mock
Journal:  J Biol Chem       Date:  2019-09-23       Impact factor: 5.157

7.  Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice.

Authors:  Wan Cheung Cheung; Joong Su Kim; Michael Linden; Liangping Peng; Brian Van Ness; Roberto D Polakiewicz; Siegfried Janz
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

8.  TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms.

Authors:  John K Simmons; Jyoti Patel; Aleksandra Michalowski; Shuling Zhang; Bih-Rong Wei; Patrick Sullivan; Ben Gamache; Kenneth Felsenstein; W Michael Kuehl; R Mark Simpson; Adriana Zingone; Ola Landgren; Beverly A Mock
Journal:  Mol Oncol       Date:  2013-12-03       Impact factor: 6.603

9.  Frap, FKBP12 rapamycin-associated protein, is a candidate gene for the plasmacytoma resistance locus Pctr2 and can act as a tumor suppressor gene.

Authors:  Valery Bliskovsky; Edward S Ramsay; John Scott; Wendy DuBois; Wei Shi; Shuling Zhang; Xiaolan Qian; Douglas R Lowy; Beverly A Mock
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-21       Impact factor: 11.205

10.  Mndal, a new interferon-inducible family member, is highly polymorphic, suppresses cell growth, and may modify plasmacytoma susceptibility.

Authors:  Ke Zhang; Daniel Kagan; Wendy DuBois; Richard Robinson; Valery Bliskovsky; William C Vass; Shuling Zhang; Beverly A Mock
Journal:  Blood       Date:  2009-08-04       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.